ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II cl…
Biotechnology
US, Winston-Salem [HQ]
Balance Sheet
5 Sheets · Starting from 2019In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Assets | 19.00 | 16.00 | 40.00 | 517.00 | 420.00 | |
|
Current
|
15.00 | 5.00 | 27.00 | 504.00 | 374.00 | |
| Cash And Equivalents | 15.00 | 4.00 | 20.00 | 490.00 | 60.00 | |
| Assets | 19.00 | 16.00 | 40.00 | 517.00 | 420.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | -1.00 | |
| Inventory | - - | - - | - - | - - | - - | |
| Short Term Investments | - - | - - | - - | - - | 302.00 | |
| Other Current Assets | - - | - - | - - | 1.00 | 9.00 | |
|
Non Current
|
4.00 | 11.00 | 13.00 | 13.00 | 46.00 | |
| Property, Plant, Equipment (Net) | 3.00 | 10.00 | 12.00 | 13.00 | 46.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | - - | |
| Other Non Current Assets | - - | - - | - - | - - | - - | |
| Liabilities | 3.00 | 6.00 | 13.00 | 13.00 | 29.00 | |
|
Current
|
2.00 | 5.00 | 12.00 | 10.00 | 25.00 | |
| Accounts Payable | - - | - - | - - | - - | 11.00 | |
| Short Term Debt | - - | - - | - - | - - | - - | |
| Deferred Revenue | - - | - - | - - | - - | -3.00 | |
| Tax Payable | - - | - - | - - | - - | 1.00 | |
| Other Current Liabilities | 2.00 | 4.00 | 9.00 | 7.00 | 22.00 | |
|
Non Current
|
1.00 | 1.00 | 1.00 | 2.00 | 4.00 | |
| Long Term Debt | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | |
| Leasing Obligations | 1.00 | 1.00 | 1.00 | 2.00 | 3.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | - - | - - | - - | - - | - - | |
| Equity | 15.00 | 9.00 | 26.00 | 504.00 | 391.00 | |
| Stockholders' Equity | 15.00 | 9.00 | 26.00 | -1,096.00 | -1,103.00 | |
| Retained Earnings | -79.00 | -106.00 | -161.00 | -1,104.00 | -1,139.00 | |
| Common Stock | 95.00 | 116.00 | 188.00 | - - | - - | |
| Preferred Stock | - - | - - | - - | - - | - - | |
| Profit | -79.00 | -26.00 | -55.00 | -148.00 | -35.00 | |
| Dividends | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | 1,601.00 | 1,494.00 | |
| Other Stockholders' Equity | - - | - - | - - | 7.00 | 36.00 | |
| Loss Other Compr. Income | - - | - - | - - | - - | - - |